Lupus is a chronic inflammatory autoimmune disease that occurs when the body’s immune system attacks its own tissues and organs. It can damage any part of the body like joints, skin, kidneys, blood cells, brain, heart and lungs. The standard treatment for lupus includes corticosteroids and antimalarial drugs which help reduce inflammation and pain associated with the disease. However, due to the heterogeneous nature of lupus there is a need for novel targeted therapies. The global biopharmaceutical industry is actively investing in R&D to develop new drugs with improved efficacy and safety for long term management of lupus.
The global Lupus Therapeutic Market is estimated to be valued at US$ 3035.59 Mn in 2023 and is expected to exhibit a CAGR of 5.6% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.
Market Dynamics:
The growing prevalence of autoimmune diseases like lupus globally is expected to drive the demand for effective lupus therapeutics over the forecast period. According to the Lupus Foundation of America, about 1.5 million Americans and at least 5 million people worldwide have a form of lupus. Developing targeted drugs that can selectively modify disease processes in lupus patients is crucial. Emerging biologic therapies hold promise to address the unmet needs. For instance, Belumosudil, an oral spleen tyrosine kinase inhibitor launched in 2022, demonstrated positive results in phase 2 clinical trial for treating lupus nephritis. Its ability to selectively inhibit B-cell signaling provides immunosuppression without general toxicity. Similarly, other pipeline drugs aiming to block key cytokines and pathways involved in the pathogenesis of lupus can usher a new era in disease management if approved. The growth opportunity offered by these novel drug classes will steer market momentum over the coming years.
Segment Analysis
The lupus therapeutic market can be segmented by product type, distribution channel, and geography. By product type, the market is dominated by the biologics segment, which accounts for over 40% share due to rising demand for targeted & specialty drugs for lupus treatment. Biologics drugs are well tolerated, customized & have fewer side effects for lupus patients. By distribution channel, hospital pharmacies dominate the segment with over 50% share as serious lupus cases require hospitalization for management & treatment involving biologics & immunosuppressant drugs.
PEST Analysis
Political: Government support in terms of favorable regulations for new drug approvals and funding for R&D of orphan drugs is driving market growth. However, pricing pressure to make drugs affordable can hamper prices of premium drugs.
Economic: Rising healthcare spending, growing disposable incomes, and increasing awareness about lupus care is fueling market revenues particularly in developed countries. However, high drug costs remain a challenge.
Social: Growing social support groups, patient advocacy drives awareness about lupus diagnosis and management. Social media is also enabling e-detailing of new treatment options to doctors and patients.
Technological: Companies are investing in developing novel drug delivery systems, biomarkers for early diagnosis and combination therapy to enhance efficacy and compliance. Blockchain solutions can improve supply chain and inventory management of drugs.
Key Takeaways
Global Lupus Therapeutic Market Demand is expected to witness high growth over the forecast period supported by rising prevalence of autoimmune disorders, advances in biologics and targeted drug delivery systems. The global Lupus Therapeutic Market is estimated to be valued at US$ 3035.59 Mn in 2023 and is expected to exhibit a CAGR of 5.6% over the forecast period 2023 to 2030.
Regional analysis comprises
The North America region accounts for over 40% market share currently owing to rising lupus disease burden, favorable reimbursements and regional presence of key market players in the US and Canada. The Asia Pacific region also shows high growth potential due to rising healthcare standards, patient affordability and increasing patient pool in China, India & Japan.
Key players related content comprises
Key players operating in the lupus therapeutic market are GlaxoSmithKline, Pfizer, F. Hoffmann-La Roche, Merck, and Bristol-Myers Squibb. These leading companies are focusing on developing novel biologics and biosimilars through collaborations to cater to the needs of various lupus patient subgroups.
*Note:
1. Source: Coherent Market Insights, Public sources, Desk research
2. We have leveraged AI tools to mine information and compile it